News – Page 110 – Endpoints News

Congress spars over whether the Biosecure Act is an overdue crackdown or a rushed witch hunt

9 months ago

FDA sends warning letter to Indian drugmaker after finding glass in injections

9 months ago

Lilly's weekly insulin hits primary endpoints in two more late-stage diabetes studies

9 months ago

Roche's dual GLP-1/GIP results show promising weight loss, but also high rates of vomiting

9 months ago

Exclusive: A male contraceptive may prevent 99% of pregnancies. Now it’s up to a small biotech to finish testing it

9 months ago

GSK to shut down UK antibiotic facility following end of Sandoz contract

9 months ago

Ionis’ $500M offering; Terns aims to raise $125M

9 months ago

Updated: Viridian reveals first Phase 3 eye disease data in bid to compete with Tepezza

9 months ago

Centessa to take narcolepsy drug into Phase 2 after no sign of side effects that doomed earlier competitor

9 months ago

Exclusive: Bain scoops up $3B for fourth life sciences fund after handful of M&A deals

9 months ago

Roivant unveils its next deal, hoping for TL1A-sized potential from a shelved Bayer lung disease therapy

9 months ago

Bayer's treatment for menopause symptoms hits primary endpoints in third late-stage trial

9 months ago

FDA advisors question whether Iterum's application for a UTI antibacterial is restrictive enough

9 months ago

House passes Biosecure Act, sending Chinese biotech ban to Senate

9 months ago

A General Catalyst-backed startup raised $38M to help workers buy health coverage on their own

9 months ago

#WCLC24 roundup: ArriVent thinks its drug can fill Tagrisso's gaps; Boehringer, Bayer's data in HER2-mutated lung ...

9 months ago

CDER chief on inspection backlog: 2025 will be a 'crucial year'

9 months ago

GSK says long-acting asthma hopeful significantly cut attacks

9 months ago

AstraZeneca, Gilead detail TROP2 ADC data in lung cancer as they search for new ways forward

9 months ago

Zealand’s GLP-1/GLP-2 drug bounces back with new Phase 1b data

9 months ago

#ESMO24 roundup: New data on Amgen’s PRMT5 inhibitor seem lackluster, and Jazz’s HER2 antibody

9 months ago

AstraZeneca's monoclonal antibody misses primary endpoint in mid-stage trial in COPD

9 months ago

Immunovant shares mid-stage Graves’ disease data; FDA lifts Rezolute’s hold

9 months ago

Bicycle Therapeutics makes an early case for its Padcev competitor: #ESMO24

9 months ago

First page Previous page 107 108 109110111 112 113 Next page Last page